KALA BIO is a clinical-stage biopharmaceutical company. It focused on the research, development and commercialization of therapies for rare and severe diseases of the eye. The company' s lead product candidate consists KPI-012. KALA BIO, formerly known as Kala Pharmaceuticals Inc., is based in ARLINGTON, Mass.
| Revenue (Most Recent Fiscal Year) | -- |
| Net Income (Most Recent Fiscal Year) | $-26.98M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | -- |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 4.13 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -- |
| Net Margin (Trailing 12 Months) | -- |
| Return on Equity (Trailing 12 Months) | -1336.10% |
| Return on Assets (Trailing 12 Months) | -94.85% |
| Current Ratio (Most Recent Fiscal Quarter) | 7.91 |
| Quick Ratio (Most Recent Fiscal Quarter) | 7.91 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $12.56 |
| Earnings per Share (Most Recent Fiscal Quarter) | -- |
| Earnings per Share (Most Recent Fiscal Year) | -- |
| Diluted Earnings per Share (Trailing 12 Months) | $-96.14 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Common Shares Outstanding | 18.59M |
| Free Float | 18.17M |
| Market Capitalization | $44.43M |
| Average Volume (Last 20 Days) | 0.09M |
| Beta (Past 60 Months) | -2.40 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 2.24% |
| Percentage Held By Institutions (Latest 13F Reports) | 24.61% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |